Biogen Inc. $BIIB Stake Lifted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 180.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 7,477 shares of the biotechnology company’s stock after purchasing an additional 4,811 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Biogen were worth $1,689,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of BIIB. Park Avenue Securities LLC increased its holdings in Biogen by 7.9% during the third quarter. Park Avenue Securities LLC now owns 7,818 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 570 shares during the last quarter. Verdence Capital Advisors LLC grew its position in shares of Biogen by 12.8% during the third quarter. Verdence Capital Advisors LLC now owns 1,600 shares of the biotechnology company’s stock worth $361,000 after purchasing an additional 182 shares in the last quarter. Leo Wealth LLC bought a new stake in Biogen during the 3rd quarter valued at approximately $5,117,000. Apollon Wealth Management LLC raised its stake in Biogen by 1,837.4% during the 3rd quarter. Apollon Wealth Management LLC now owns 42,817 shares of the biotechnology company’s stock valued at $9,672,000 after purchasing an additional 40,607 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in Biogen by 27.8% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 7,913 shares of the biotechnology company’s stock worth $1,787,000 after purchasing an additional 1,720 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB stock opened at $253.62 on Monday. Biogen Inc. has a twelve month low of $146.52 and a twelve month high of $258.78. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 108.38, a price-to-earnings-growth ratio of 2.88 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The firm’s fifty day simple moving average is $227.08 and its two-hundred day simple moving average is $201.04.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.63. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business earned $4.81 EPS. As a group, analysts anticipate that Biogen Inc. will post 12.44 earnings per share for the current year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Biogen from $248.00 to $272.00 and gave the company a “buy” rating in a research report on Thursday. Bank of America boosted their price target on shares of Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research note on Thursday, October 22nd. Wells Fargo & Company increased their price objective on shares of Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Weiss Ratings lowered Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $260.00 target price (up from $235.00) on shares of Biogen in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biogen presently has an average rating of “Moderate Buy” and an average target price of $251.00.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.